|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
20
|
|
pubmed:dateCreated |
2005-3-22
|
|
pubmed:abstractText |
Recombinant subunit protein vaccines generally elicit good humoral immune responses, weak helper T cell responses and no cytotoxic T cell responses. Certain adjuvants are known to enhance humoral and cellular immune responses. This study evaluated the humoral, CD4+ T helper and CTL responses induced by the recombinant SL* protein adjuvanted with AS02A in comparison with non-adjuvanted SL* in PBS in two groups of 15 healthy adult volunteers. The AS02A adjuvant contains monophosphoryl lipid A (MPL), QS21 and an oil in water emulsion. The adjuvanted vaccine induced fast and vigorous humoral and helper T cell responses of the Th1 type. Using a pool of overlapping 20mer peptides a cytotoxic response was detected in 6 out of 14 HLA-A2-positive (+) and HLA-A2-negative (-) recipients of the adjuvanted vaccine. All HLA-A2-positive subjects in the adjuvanted group and up to 30% of the subjects in the SL* PBS group displayed a CTL response against selected HLA-A2-restricted CD8+ T cell epitopes. The non-adjuvanted vaccine induced a very weak antibody response and no helper T cell responses. Local and general reactions were more frequently reported by AS02A recipients than in the non-adjuvanted group but the safety profile was considered acceptable. AS02A can be considered as a useful adjuvant that strongly enhances the cellular and humoral responses of subunit protein vaccines.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Adjuvants, Immunologic,
http://linkedlifedata.com/resource/pubmed/chemical/Cytokines,
http://linkedlifedata.com/resource/pubmed/chemical/Drug Combinations,
http://linkedlifedata.com/resource/pubmed/chemical/Hepatitis B Antibodies,
http://linkedlifedata.com/resource/pubmed/chemical/Hepatitis B Vaccines,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon-gamma,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-5,
http://linkedlifedata.com/resource/pubmed/chemical/Lipid A,
http://linkedlifedata.com/resource/pubmed/chemical/Phytohemagglutinins,
http://linkedlifedata.com/resource/pubmed/chemical/Saponins,
http://linkedlifedata.com/resource/pubmed/chemical/Vaccines, Synthetic
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0264-410X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
8
|
|
pubmed:volume |
23
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2591-601
|
|
pubmed:dateRevised |
2008-11-21
|
|
pubmed:meshHeading |
pubmed-meshheading:15780441-Adjuvants, Immunologic,
pubmed-meshheading:15780441-Adult,
pubmed-meshheading:15780441-Amino Acid Sequence,
pubmed-meshheading:15780441-Antibody Formation,
pubmed-meshheading:15780441-Cell Proliferation,
pubmed-meshheading:15780441-Cell Separation,
pubmed-meshheading:15780441-Cytokines,
pubmed-meshheading:15780441-Drug Combinations,
pubmed-meshheading:15780441-Hepatitis B Antibodies,
pubmed-meshheading:15780441-Hepatitis B Vaccines,
pubmed-meshheading:15780441-Humans,
pubmed-meshheading:15780441-Immunity, Cellular,
pubmed-meshheading:15780441-Interferon-gamma,
pubmed-meshheading:15780441-Interleukin-5,
pubmed-meshheading:15780441-Lipid A,
pubmed-meshheading:15780441-Molecular Sequence Data,
pubmed-meshheading:15780441-Neutrophils,
pubmed-meshheading:15780441-Phytohemagglutinins,
pubmed-meshheading:15780441-Saponins,
pubmed-meshheading:15780441-T-Lymphocytes, Cytotoxic,
pubmed-meshheading:15780441-Vaccines, Synthetic
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Potent enhancement of cellular and humoral immune responses against recombinant hepatitis B antigens using AS02A adjuvant in healthy adults.
|
|
pubmed:affiliation |
GlaxoSmithKline Biologicals, 89 Rue de 1'institut, B-1330 Rixensart, Belgium. pierre.vandepapeliere@gskbio.com
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Clinical Trial, Phase II,
Clinical Trial, Phase I
|
